Medicare Enrolled
Dr. Thomas Katta, MD
Hematology & Oncology · Orlando, FL
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Katta from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Katta?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Katta
Dr. Thomas Katta is a hematology & oncology specialist in Orlando, FL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Katta performed 6,154 Medicare services across 1,087 unique beneficiaries.
Between the years covered by Open Payments, Dr. Katta received a total of $21,214 from 89 pharmaceutical and/or device companies across 1061 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Katta is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 28% volume in FL
$21,214 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 39331 | Clear | January 31, 2027 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗6,154
Medicare services
Top 28% in FL for hematology & oncology
1,087
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~324 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 1,713 | $0 | $4 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,010 | $8 | $10 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
999 | $8 | $35 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
923 | $91 | $209 |
| Flow cytometry, additional marker An additional marker is tested during a flow cytometry procedure to analyze DNA or cells. This step adds specific data points to the initial analysis. |
530 | $17 | $98 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
248 | $94 | $275 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
199 | $10 | $48 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
135 | $63 | $203 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
111 | $99 | $271 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
79 | $12 | $45 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
49 | $135 | $399 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
46 | $52 | $144 |
| New patient office visit, complex (60-74 min) | 38 | $171 | $404 |
| Flow cytometry DNA or cell analysis, first marker A laboratory test that uses a laser to analyze cells or DNA by detecting a specific marker on the cell surface or within the cell. |
26 | $47 | $161 |
| Flow cytometry, 16 or more markers A laboratory test that uses lasers to analyze cells or DNA using 16 or more different markers. This technique helps identify and characterize specific cell types based on their physical and chemical properties. |
20 | $65 | $208 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
17 | $1 | $20 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $120 | $275 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.8% high complexity
33.4% medium
64.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$21,214
Total received (2018-2024)
Avg $3,031/year across 7 years
Top 25% in FL for hematology & oncology
89
Companies
1,061
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$20,706 (97.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$508 (2.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,036
2023
$3,706
2022
$3,369
2021
$3,233
2020
$2,150
2019
$2,273
2018
$2,447
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,827
Incyte Corporation
$1,459
AstraZeneca Pharmaceuticals LP
$1,275
Janssen Biotech, Inc.
$1,240
PFIZER INC.
$1,216
Celgene Corporation
$1,195
Astellas Pharma US Inc
$1,187
E.R. Squibb & Sons, L.L.C.
$1,052
GENZYME CORPORATION
$770
Lilly USA, LLC
$671
Daiichi Sankyo Inc.
$528
Merck Sharp & Dohme LLC
$496
Seagen Inc.
$470
Merck Sharp & Dohme Corporation
$362
Karyopharm Therapeutics Inc.
$352
Pharmacyclics LLC, An AbbVie Company
$319
Regeneron Healthcare Solutions, Inc.
$297
Alexion Pharmaceuticals, Inc.
$294
Bayer HealthCare Pharmaceuticals Inc.
$282
Eisai Inc.
$272
Genentech USA, Inc.
$264
GlaxoSmithKline, LLC.
$260
Exelixis Inc.
$253
Janssen Pharmaceuticals, Inc
$252
Boehringer Ingelheim Pharmaceuticals, Inc.
$242
Bayer Healthcare Pharmaceuticals Inc.
$238
Takeda Pharmaceuticals U.S.A., Inc.
$228
Blueprint Medicines Corporation
$222
Amgen Inc.
$219
Puma Biotechnology, Inc.
$209
ARRAY BIOPHARMA INC
$201
Kite Pharma, Inc.
$180
Taiho Oncology, Inc.
$155
JAZZ PHARMACEUTICALS INC.
$130
SOBI, INC
$124
Johnson & Johnson Health Care Systems Inc.
$115
BeiGene USA, Inc.
$112
ABBVIE INC.
$105
Dova Pharmaceuticals
$105
Genmab U.S., Inc.
$99
PUMA BIOTECHNOLOGY, INC.
$98
Agios Pharmaceuticals, Inc.
$96
Stemline Therapeutics Inc.
$83
Epizyme, Inc.,
$83
G1 Therapeutics, Inc.
$82
EMD Serono, Inc.
$80
SEAGEN INC.
$75
Janssen Scientific Affairs, LLC
$75
Sumitomo Pharma America, Inc.
$73
Foundation Medicine, Inc.
$73
Seattle Genetics, Inc.
$55
Pharmacyclics LLC, an AbbVie Company
$52
Myovant Sciences Inc.
$49
Gilead Sciences, Inc.
$47
Verastem, Inc.
$46
Pharmacosmos Therapeutics Inc.
$44
CTI BioPharma Corp.
$44
Sun Pharmaceutical Industries Inc.
$41
Heron Therapeutics, Inc.
$41
Deciphera Pharmaceuticals Inc.
$38
Alnylam Pharmaceuticals Inc.
$37
Clovis Oncology, Inc.
$35
Emmaus Medical, Inc.
$35
Verity Pharmaceuticals Inc.
$34
AMAG Pharmaceuticals, Inc.
$33
TAIHO ONCOLOGY, INC.
$32
EUSA Pharma (US) LLC
$31
MorphoSys, US Inc.
$30
SUN PHARMACEUTICAL INDUSTRIES INC.
$28
TerSera Therapeutics LLC
$25
SpringWorks Therapeutics, Inc.
$24
Fennec Pharmaceuticals, Inc.
$23
EISAI INC.
$23
Mirati Therapeutics, Inc.
$22
Dendreon Pharmaceuticals LLC
$21
TOLMAR Pharmaceuticals, Inc.
$20
Tolmar, Inc.
$20
ADC Therapeutics America, Inc.
$20
Array BioPharma Inc.
$20
Kyowa Kirin, Inc.
$19
GT Medical Technologies, Inc
$19
Aveo Pharmaceuticals, Inc.
$18
Rigel Pharmaceuticals, Inc.
$18
Global Blood Therapeutics, Inc.
$17
Grifols USA, LLC
$16
AbbVie Inc.
$15
Sobi, Inc
$14
Amarin Pharma Inc.
$11
Kerecis Limited
$5
Top 3 companies account for 21.5% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BLENREP · BOSULIF · BOTOX · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CINVANTI · COSELA · COSENTYX · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Endari · Enhertu · Epkinly · Erleada · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAMMATILE · GILOTRIF · GIVLAARI · Gamunex-C · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · Inrebic · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kerecis Omega3 Wound · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · Monoferric · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROSTATE CANCER - DISEASE · PROVENGE · PYRUKYND · Padcev · Pedmark · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SPRYCEL · SUSTOL · SUTENT · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Trelstar · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · Vanflyta · Vascepa · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $345 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
49
Per 100K population
3.4
County median income
$77,011
Nearest hospital
ORLANDO HEALTH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Katta is a clinical cardiology specialist, with above-average Medicare volume (top 28% in FL), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Katta experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Katta performed 1,713 anti-nausea injection (ondansetron/zofran) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Katta receive payments from pharmaceutical companies?
Yes. Dr. Katta received a total of $21,214 from 89 companies across 1,061 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Katta's costs compare to other hematology & oncology specialists in Orlando?
Dr. Katta's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Katta) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Orlando
Browse hematology & oncology specialists in Orlando ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology